MA41636A - Méthode de traitement de la cholangite sclérosante primitive - Google Patents

Méthode de traitement de la cholangite sclérosante primitive

Info

Publication number
MA41636A
MA41636A MA041636A MA41636A MA41636A MA 41636 A MA41636 A MA 41636A MA 041636 A MA041636 A MA 041636A MA 41636 A MA41636 A MA 41636A MA 41636 A MA41636 A MA 41636A
Authority
MA
Morocco
Prior art keywords
sclerosant
cholangitis
primitive
treatment
sclerosant cholangitis
Prior art date
Application number
MA041636A
Other languages
English (en)
Inventor
Brihad Abhyankar
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA41636A publication Critical patent/MA41636A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA041636A 2015-03-06 2016-03-03 Méthode de traitement de la cholangite sclérosante primitive MA41636A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562129698P 2015-03-06 2015-03-06

Publications (1)

Publication Number Publication Date
MA41636A true MA41636A (fr) 2018-01-09

Family

ID=55699788

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041636A MA41636A (fr) 2015-03-06 2016-03-03 Méthode de traitement de la cholangite sclérosante primitive

Country Status (11)

Country Link
US (2) US20180051086A1 (fr)
EP (2) EP4257200A3 (fr)
JP (1) JP6942053B2 (fr)
KR (1) KR20170120622A (fr)
AU (1) AU2016229193A1 (fr)
BR (1) BR112017019071A2 (fr)
CA (1) CA2978725A1 (fr)
EA (1) EA201791970A1 (fr)
MA (1) MA41636A (fr)
MX (1) MX2017011272A (fr)
WO (1) WO2016144720A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
WO2017160700A1 (fr) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
CA3017743A1 (fr) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methode de traitement de la reaction du greffon contre l'hote (gvd)
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
MA55735A (fr) * 2019-04-17 2022-02-23 Millennium Pharm Inc Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23
BR112021024897A2 (pt) * 2019-06-10 2022-01-18 Takeda Pharmaceuticals Co Métodos de produção de um anticorpo anti-a4ss7
MX2023003401A (es) 2020-10-08 2023-04-25 Curome Biosciences Co Ltd Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2025038708A1 (fr) * 2023-08-14 2025-02-20 Paragon Therapeutics, Inc. PROTÉINES DE LIAISON À L'INTÉGRINE α4β7 ET PROCÉDÉS D'UTILISATION

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
JP4205162B2 (ja) 1995-02-10 2009-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 粘膜血管アドレシンおよびその用途
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1999058573A1 (fr) * 1998-05-13 1999-11-18 Genentech, Inc. Diagnostic et traitement des troubles hepatiques
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
EP1507756B1 (fr) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Inhibiteurs de ccr9 et utilisation de ceux-ci
DK1798223T4 (da) 2002-11-18 2014-09-22 Chemocentryx Inc Arylsulfonamider
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
EP2408816B1 (fr) 2009-03-20 2019-09-04 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
EP3265492A1 (fr) 2018-01-10
JP6942053B2 (ja) 2021-09-29
EP4257200A3 (fr) 2024-01-03
EP4257200A2 (fr) 2023-10-11
KR20170120622A (ko) 2017-10-31
US12391760B2 (en) 2025-08-19
MX2017011272A (es) 2018-01-12
CA2978725A1 (fr) 2016-09-15
EA201791970A1 (ru) 2018-07-31
JP2018508526A (ja) 2018-03-29
BR112017019071A2 (pt) 2018-04-17
US20180051086A1 (en) 2018-02-22
AU2016229193A1 (en) 2017-09-21
WO2016144720A1 (fr) 2016-09-15
US20210388092A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
EP3288383A4 (fr) Méthodes de traitement du cancer
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
EP3261641A4 (fr) Traitement de la pancréatite
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
EP3341080A4 (fr) Méthode de traitement du cancer
PL3288581T3 (pl) Sposób leczenia nowotworu
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
HUE048265T2 (hu) Eljárás PD-L1 mennyiségi meghatározására
FR25C1031I1 (fr) Traitement de maladies cholestatiques intrahepatiques
EP3375440A4 (fr) Méthode de traitement de la mucosite
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3307280A4 (fr) Traitement de dysfonction sexuelle
MA41462A (fr) Méthode de traitement de maladies
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
EP3448365A4 (fr) Méthode de traitement de la constipation
IL257764B (en) Methods for treatment of diseases
PL3393468T3 (pl) Metody leczenia niedoboru odporności
EP3389652A4 (fr) Méthodes de traitement du cancer
EP3355890A4 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA42930A (fr) Traitement de maladies neurodégénératives
EP3328384A4 (fr) Traitement de la fibrose
IL253847A0 (en) Methods of treating diseases
LT3209319T (lt) Grybelinių infekcijų gydymo būdas
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego